Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Alexion"

11 News Found

AstraZeneca’s new R&D Centre and Alexion HQ in Cambridge, Massachusetts
News | May 01, 2022

AstraZeneca’s new R&D Centre and Alexion HQ in Cambridge, Massachusetts

Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub


Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development
People | July 31, 2025

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development

He most recently served as Chief Medical Officer of AstraZeneca and Alexion


Voydeya approved in the EU as add-on treatment to ravulizumab
News | April 23, 2024

Voydeya approved in the EU as add-on treatment to ravulizumab

ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue


Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
Drug Approval | March 27, 2024

Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+


AstraZeneca to acquire Amolyt Pharma
News | March 18, 2024

AstraZeneca to acquire Amolyt Pharma

Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition


DTx Pharma appoints Peter Condon as Chief Business Officer
People | June 29, 2022

DTx Pharma appoints Peter Condon as Chief Business Officer

Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.


Ultomiris approved in the US for adults with generalised myasthenia gravis
Drug Approval | April 29, 2022

Ultomiris approved in the US for adults with generalised myasthenia gravis

Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks


AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
Biotech | March 01, 2022

AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006

Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m


AstraZeneca partners with Honeywell to develop next-gen respiratory inhalers
Sustainability | February 22, 2022

AstraZeneca partners with Honeywell to develop next-gen respiratory inhalers

New inhalers would have near-zero Global Warming Potential propellant


AstraZeneca and Neurimmune to develop and commercialise NI006
Biotech | January 07, 2022

AstraZeneca and Neurimmune to develop and commercialise NI006

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition